Catalent has entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO (pralsetinib). GAVRETO is a new therapy developed by Blueprint Medicines for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This agreement will continue Catalent’s involvement in the GAVRETO program, which has been supported by Catalent’s Nottingham, U.K., site since 2015.   GAVRETO is a once-dai...